Last update 08 Nov 2025

Calcipotriol/LEO-80122

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Calcipotriol/LEO 80122, LEO 19123, LEO-19123
Target
VDR
Action
agonists
Mechanism
VDR agonists(Vitamin D receptor agonists)
Therapeutic Areas
Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Dermatitis, AtopicEczemaPlaque psoriasis+ [1]
Originator Organization
Leo Pharma, Inc.Leo Pharma, Inc.
Active Organization-
Inactive Organization
LEO Pharma A/SLEO Pharma A/SLeo Pharma, Inc.Leo Pharma, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Calcipotriol/LEO-80122
NCT00764751
/ CompletedPhase 2
LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
100 Clinical Results associated with Calcipotriol/LEO-80122
Login to view more data
100 Translational Medicine associated with Calcipotriol/LEO-80122
Login to view more data
100 Patents (Medical) associated with Calcipotriol/LEO-80122
Login to view more data
100 Deals associated with Calcipotriol/LEO-80122
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Psoriasis vulgarisPhase 2
Canada
Leo Pharma, Inc.Leo Pharma, Inc.
01 Sep 2008
Dermatitis, AtopicPhase 2
Canada
Leo Pharma, Inc.Leo Pharma, Inc.
01 Oct 2006
Dermatitis, AtopicPhase 2
Denmark
Leo Pharma, Inc.Leo Pharma, Inc.
01 Oct 2006
Dermatitis, AtopicPhase 2
Finland
Leo Pharma, Inc.Leo Pharma, Inc.
01 Oct 2006
Dermatitis, AtopicPhase 2
United Kingdom
Leo Pharma, Inc.Leo Pharma, Inc.
01 Oct 2006
EczemaPhase 2
United Kingdom
LEO Pharma A/SLEO Pharma A/S
-
Plaque psoriasisPhase 2
Canada
LEO Pharma A/SLEO Pharma A/S
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT00764751 (CTgov)
Phase 2
Psoriasis vulgaris
51
(Group A: LEO 19123)
ncprlfaepn(ncquelrqrw) = pxkwfgpsdn nftxckxyit (nidweyzjvc, 33.2)
View more
-
06 May 2019
(Group A: Dovonex®)
ncprlfaepn(ncquelrqrw) = cskmboutlu nftxckxyit (nidweyzjvc, 27.8)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free